Patents Examined by Karlheinz R. Skowronek
  • Drug transporter permeating blood-brain barrier, peptide and use thereof
    Patent number: 9156889
    Abstract: A peptide, wherein the peptide comprises an amino acid sequence expressed by the following SEQ ID NO: 1, an amino acid sequence expressed by the following SEQ ID NO: 2, an amino acid sequence expressed by the following SEQ ID NO: 3, an amino acid sequence expressed by the following SEQ ID NO: 4, or any combination thereof: (SEQ?ID?NO:?1) ALGDSLYGAASLN; (SEQ?ID?NO:?2) MTVDNPASTTNKDKLFSVWK; (SEQ?ID?NO;?3) PGAVPEK; and (SEQ?ID?NO:?4) STKDLTTY.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: October 13, 2015
    Assignee: Microbial Chemistry Research Foundation
    Inventors: Akio Nomoto, Coh-ichi Nihei
  • Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent
    Patent number: 9155799
    Abstract: The disclosure describes collagen constructs comprising antimicrobial agents and related methods.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 13, 2015
    Assignee: MiMedx Group, Inc.
    Inventor: Thomas J. Koob
  • Chromatography media
    Patent number: 9156879
    Abstract: The present invention provides, in part, a chromatographic restricted access media comprising aminopropyl groups derivatized with polysuccinamide that is derivatized with 1-ethylpropylamine and denatured human serum albumin. Methods of purifying polypeptides and complexes thereof are also provided.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: October 13, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Lev Z. Vilenchik, Krishna Kalghatgi
  • Use of melanocortins to treat insulin sensitivity
    Patent number: 9155777
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: October 13, 2015
    Assignees: Ipsen Pharma S.A.S., Louisiana State University
    Inventors: Heather A. Halem, Michael Dewitt Culler, Andrew A. Butler
  • Thrombomodulin variants and use thereof
    Patent number: 9156904
    Abstract: A pharmaceutical composition comprising an effective amount of a mutant thrombomodulin is disclosed. The mutant thrombomodulin comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 2 and has residues corresponding to Ala364 and Ala391 of SEQ ID NO: 2. The mutant thrombomodulin has little or no protein C activation activity, and is effective in promoting wound healing and accelerating closure of an open wound in a diabetic.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: October 13, 2015
    Assignee: Blue Blood Biotech Corp.
    Inventors: Hua-Lin Wu, Guey-Yueh Shi
  • Antimicrobial fusion compounds and uses thereof
    Patent number: 9155800
    Abstract: A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: October 13, 2015
    Assignee: VALIANT BIOPHARMA SDN BHD
    Inventors: Muhammad Sagaf Abu Bakar, Ag., Eng Huan Ung
  • Tyrosine ligation process
    Patent number: 9149541
    Abstract: A process is provided for preparing a conjugate of Formula (I-A) or (I) comprising a polypeptide containing n number of tyrosine units, where n is an integer greater than or equal to 1, dispersed within the amino acid chain having and amino terminus end (A1) and an acid terminus end (A2) of the protein or polypeptide and having a weight average molecular weight equal to or greater than 10,000 Daltons (10 kDa), wherein the conjugate comprises a number m of tyrosine conjugates (modified tyrosine residues) as depicted in Formula (I-A) or (I), where m is at least one and is less than or equal to n: where X, Lg, L and R are as defined herein.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: October 6, 2015
    Assignee: NOVARTIS AG
    Inventors: Roberto Adamo, Martin Allen, Francesco Berti, Elisa Danieli, Qi-Ying Hu
  • Method and pharmacological composition for the diagnosis and treatment of male sub-fertility
    Patent number: 9149513
    Abstract: Methods for treating male sub-fertility by administering a pharmaceutical composition to a subject in need thereof are provided. The pharmaceutical compositions include an agent that causes a reduction in an effect of extracellular DNA on sperm cells. The agent may be, for example, an enzyme that degrades DNA such as DNase, a substance that blocks the interaction between cell free DNA and sperm cell surface receptors, a substance that binds to DNA, a substance that inhibits endogenous sperm cell DNase, a substance that inhibits a member of a signal transduction pathway mediated by DNA binding to sperm cell surface receptors, or an agent that stimulates production of an endogenous substance that causes a reduction in an antifertility effect of cell free DNA on sperm cells.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 6, 2015
    Assignee: PERINESS LTD.
    Inventors: Benjamin Bartoov, Ronen Yehuda, Melamed Dobroslav
  • Conjugated factor VIII molecules
    Patent number: 9150848
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: October 6, 2015
    Assignee: Novo Nordisk A/s
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
    Patent number: 9150618
    Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scleritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: October 6, 2015
    Assignee: Xigen Inflammation Ltd.
    Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie
  • Variant of antihemophilic factor VIII having increased specific activity
    Patent number: 9150637
    Abstract: The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor VIII having increased specific activity in comparison to known factor VIII products.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: October 6, 2015
    Assignees: BAXALTA INC., BAXALTA GMBH
    Inventors: Chee Kong Lai, Roddy Kevin Stafford
  • Procoagulant peptides and their derivatives and uses therefor
    Patent number: 9149511
    Abstract: The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analog sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: October 6, 2015
    Assignee: Ethicon, Inc.
    Inventors: Yi-Lan Wang, Guanghui Zhang
  • Modified factor X polypeptides and uses thereof
    Patent number: 9145552
    Abstract: Modified therapeutic proteins are provided. In particular modified Factor X polypeptides, which includes the Factor X zymogen, Factor Xa and other forms of Factor X, and uses thereof are provided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 29, 2015
    Assignee: Catalyst Biosciences, Inc.
    Inventors: Edwin L. Madison, Christopher Thanos
  • Versatile native chemical ligation technologies
    Patent number: 9145440
    Abstract: Novel methods of native chemical ligation are provided. The methods involve reacting a thioacid (e.g. a peptide thioacid) with an aziridinyl compound (e.g. an aziridinyl peptide) or glycosylamine under mild conditions without the use of protecting groups, and without requiring that a cysteine residue be present in the ligation product. Initial coupling of the thioacid and the aziridinyl compound yields a ligation product containing an aziridinyl ring. Optional subsequent opening of the aziridinyl ring (e.g. via a nucleophilic attack) produces a linearized and modified ligation product. Coupling of a peptide thioacid and glycosylamine yields a glycosylated peptide.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 29, 2015
    Assignee: Washington State University
    Inventor: Philip Garner
  • Protein-polymer-drug conjugates
    Patent number: 9144615
    Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight ?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: September 29, 2015
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Aleksandr Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Charles E. Hammond, Cheri A. Stevenson, Natalya D. Bodyak, Patrick R. Conlon, Dmitry R. Gumerov
  • Active agent prodrugs with heterocyclic linkers
    Patent number: 9139612
    Abstract: The embodiments provide prodrug compounds of Formulae I-XVII. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XVII that provides controlled release of an active agent. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an active agent from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: September 22, 2015
    Assignee: Signature Therapeutics, Inc.
    Inventors: Thomas E. Jenkins, Craig O. Husfeld
  • Isolation, identification, and uses of antifungal compounds
    Patent number: 9139616
    Abstract: In one aspect, the invention relates to isolated compounds useful as antifungal agents, for example, compounds having a structure represented by a formula: wherein R1 is hydrogen or hydroxyl; wherein R2 is hydrogen or xylose; and wherein R3 and R4 are each hydrogen or together oxygen, or a pharmaceutically acceptable salt thereof; methods of isolating and purifying same; pharmaceutical compositions comprising same; agricultural compositions comprising same; and methods of treating and/or preventing fungal infections using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: September 22, 2015
    Assignee: University of Utah Research Foundation
    Inventors: Eric W. Schmidt, Joseph O. Falkinham, Peter W. Jeffs
  • Activating adiponectin by casein hydrolysate
    Patent number: 9138455
    Abstract: The present disclosure provides a method for activating adiponectin by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce risk of heart attack and help in maintaining healthy weight. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 22, 2015
    Assignee: Mead Johnson Nutrition Company
    Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers, Tania Romacho, Manuela Elsen, Jürgen Eckel
  • Maintenance therapy regime/regimen for the treatment of acne
    Patent number: 9132139
    Abstract: A novel maintenance therapy regime/regimen for the treatment of acne related diseases includes administering an oral antibiotic with a topical fixed-dose combination of a retinoid, such as adapalene, and an anti-bacterial agent, such as benzoyl peroxide.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: September 15, 2015
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Charles Dhuin, Nabil Kerrouche, Stéphanie Arsonnaud, Pascale Soto
  • Protein screening methods
    Patent number: 9134304
    Abstract: The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: September 15, 2015
    Assignee: X-Body, Inc.
    Inventors: Richard W. Wagner, Alexander Litovchick, Yan Chen